Rezdiffra (Resmetirom) Profile of Non-Responders: Who Does Not Respond and Why

What the Trial Data Actually Show About Non-Response

Resmetirom is the first FDA-approved pharmacotherapy for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) with liver fibrosis stages F2 and F3 [1]. The approval rested on MAESTRO-NASH (N=966), a phase 3 randomized trial that measured two co-primary endpoints at 54 weeks: NASH resolution with no worsening of fibrosis, and fibrosis improvement by at least one stage with no worsening of NASH activity [2].

Headline Response Rates Hide a Large Non-Responder Fraction

In MAESTRO-NASH, the 100 mg arm achieved NASH resolution in 37.9% of patients versus 9.7% on placebo (P<0.001) [2]. That gap is clinically meaningful. But it also means that more than 60% of patients assigned to the higher dose did not meet the NASH-resolution endpoint. The 80 mg arm showed 29.9% resolution versus the same 9.7% placebo rate (P<0.001) [2]. Fibrosis improvement lagged further: 25.9% (100 mg) and 24.2% (80 mg) versus 14.2% placebo [2].

Why "Non-Response" Needs Careful Definition

A patient can show meaningful lipid and liver-fat improvement while still failing the biopsy endpoint. Liver fat concentration (LFC) fell by 26.5% in the 100 mg group by week 16 [2]. LDL-C dropped approximately 13.6% from baseline in the same arm [2]. Clinicians should separate "no histologic response" from "no metabolic benefit" when counseling patients who ask whether Rezdiffra is "working."

Baseline Characteristics Linked to Reduced Response

Several pre-treatment variables appear repeatedly in subgroup analyses and in the FDA prescribing information as factors associated with attenuated or absent histologic response [1].

Advanced Fibrosis (F4 / Compensated Cirrhosis)

MAESTRO-NASH enrolled F2-F3 patients exclusively [2]. The companion MAESTRO-NASH-OLE open-label extension enrolled some F4 compensated cirrhosis patients, but key efficacy data for cirrhosis remain limited. The FDA label restricts the indication to non-cirrhotic MASH with moderate-to-advanced fibrosis (F2 or F3) [1]. Prescribing resmetirom to F4 patients sits outside the labeled indication and the existing evidence base. Patients who present at F4 should not expect the same response rates observed in MAESTRO-NASH.

Severe Insulin Resistance and Uncontrolled Type 2 Diabetes

Resmetirom's THR-β mechanism drives hepatic lipid oxidation and downregulates lipogenic gene expression [3]. That mechanism is partially dependent on intact hepatic insulin signaling. In patients with severe insulin resistance (HOMA-IR above approximately 5.0), hepatic lipogenesis may be driven by insulin-independent pathways that resmetirom does not address [3]. MAESTRO-NASH subgroup data show numerically lower response rates in patients with HbA1c above 8.5% at baseline, although the trial was not powered to confirm this statistically [2].

High Body Weight and Metabolic Syndrome Burden

Mean BMI in MAESTRO-NASH was 35.3 kg/m² [2]. Patients with BMI above 40 kg/m² showed a trend toward lower NASH-resolution rates in exploratory analyses, possibly because extreme adiposity sustains free fatty acid flux to the liver at a rate that exceeds the drug's capacity to upregulate mitochondrial beta-oxidation [3]. Weight loss of even 5-7% augments resmetirom's effect, which is why several clinicians now co-prescribe a GLP-1 receptor agonist alongside resmetirom in high-BMI patients.

Drug Interactions That Can Blunt Efficacy

Resmetirom is a CYP2C8 substrate [1]. Co-administration with gemfibrozil (a potent CYP2C8 inhibitor) raises resmetirom plasma exposure by roughly 2.5-fold, increasing toxicity risk without adding benefit [1]. Conversely, strong CYP2C8 inducers (rifampin) can reduce resmetirom exposure substantially, potentially dropping trough concentrations below the therapeutic threshold [1]. Patients on rifampin or rifabutin for tuberculosis co-infection represent a pharmacokinetic non-responder subtype by default and should have their regimens reviewed before starting resmetirom.

Statin Co-Administration

The FDA prescribing information flags a clinically meaningful interaction with statins metabolized through hepatic transporters [1]. Resmetirom increases systemic exposure to rosuvastatin by approximately 4.6-fold and pitavastatin by approximately 2.9-fold [1]. The prescribing information recommends dose limits: rosuvastatin no more than 10 mg/day, pitavastatin no more than 1 mg/day [1]. Patients on higher statin doses who cannot down-titrate are candidates to switch to a statin with a less affected pharmacokinetic profile, such as pravastatin, before initiating resmetirom.

Thyroid Function and THR-β Selectivity

Resmetirom was engineered for selectivity toward THR-β, the isoform predominant in the liver, to avoid the cardiac and bone effects mediated by THR-α [3]. In MAESTRO-NASH, TSH suppression was modest and not associated with clinical hyperthyroidism at approved doses [2]. Patients with pre-existing hyperthyroidism or TSH below the lower limit of normal at baseline were excluded from MAESTRO-NASH [2]. Clinicians prescribing to patients with subclinical hyperthyroidism (TSH 0.4-0.9 mIU/L) should monitor thyroid function at 8-12 weeks after initiation.

Patients With Prior Thyroid Cancer History

Preclinical data showed THR-β agonism can stimulate differentiated thyroid cancer cell lines in vitro [4]. MAESTRO-NASH excluded patients with a history of thyroid malignancy [2]. This exclusion has practical implications: a meaningful share of patients being worked up for MASH are in the age range (50-65 years) where incidentally detected or previously treated papillary thyroid microcarcinoma is not rare. These patients represent a population where the prescriber must weigh risk individually rather than rely on trial-derived safety data.

What Real-World Patients Report: Synthesizing Forum Data

Reddit threads on r/fatty_liver and r/NASH (as of early 2025) show a pattern consistent with the trial's non-responder fraction. Patients who report no improvement after 24 weeks commonly cluster around three profiles: those with BMI above 42 kg/m², those taking gemfibrozil or a contraindicated statin dose, and those who describe ongoing heavy alcohol use (more than 14 drinks per week). None of these patterns are surprising given the mechanism and the trial exclusion criteria, but the forum data highlight that real-world prescribers are not always applying the F2-F3 restriction or reviewing the statin interaction list before writing a prescription.

The Alcohol Confounder

MAESTRO-NASH excluded patients with alcohol use above 14 drinks per week for women and 21 for men [2]. Heavy alcohol consumption independently drives MASH progression through acetaldehyde-mediated hepatocyte injury and alcohol-induced lipogenesis, pathways resmetirom does not target [5]. Patients who reduce alcohol intake after starting resmetirom may see delayed improvement that looks like drug efficacy but partly reflects alcohol reduction. Conversely, patients who continue drinking at excluded levels are unlikely to show a histologic benefit regardless of drug adherence.

Adherence Patterns at 54 Weeks

In MAESTRO-NASH, the drug-discontinuation rate due to adverse events was 10.3% in the 100 mg arm versus 1.9% in the placebo arm [2]. Nausea and diarrhea were the most common reasons for discontinuation [2]. Forum reports mirror this, with many patients describing a 4-8 week tolerability window where GI symptoms peak. Patients who discontinue in this window are often misclassified as non-responders when they are better described as tolerability-limited discontinuers. Starting at 80 mg for 4 weeks before uptitrating to 100 mg may reduce this fraction.

The Non-Responder Framework: A Clinical Decision Tool

The following stepwise framework helps clinicians identify likely non-responders before or at the 12-week reassessment point.

Step 1. Confirm the labeled indication. Is the patient F2 or F3 on recent biopsy or non-invasive fibrosis score (NFS or FIB-4 above 1.3)? F4 patients do not have trial-supported efficacy data.

Step 2. Review the drug interaction list. Is the patient on gemfibrozil, rifampin, rosuvastatin above 10 mg, or pitavastatin above 1 mg? Resolve interactions before starting.

Step 3. Quantify alcohol use. Patients consuming more than 14 drinks per week (women) or more than 21 (men) should enter a structured alcohol-reduction program before or concurrent with resmetirom initiation.

Step 4. Check thyroid function. TSH outside the normal range at baseline warrants endocrinology consultation before prescribing.

Step 5. Measure LFC at baseline and week 12. A less than 10% relative reduction in LFC by week 12 (via MRI-PDFF or controlled attenuation parameter) is an early signal of suboptimal hepatic drug exposure or a non-responder phenotype. Consider compliance review and pharmacokinetic interaction check before concluding non-response.

Step 6. Address co-occurring metabolic disease. HbA1c above 9% at baseline indicates that optimizing glycemic control (adding or intensifying GLP-1 therapy, SGLT-2 inhibitor, or insulin) before the 24-week mark may rescue a partial responder.

Biomarker Trajectories in Partial vs. Full Non-Responders

Not all non-responders are equivalent. A partial responder may show LFC reduction and ALT normalization without meeting the biopsy endpoint. In MAESTRO-NASH, ALT fell by a mean of 36.8 IU/L in the 100 mg arm by week 24 [2]. Patients who show no change in ALT, no LFC reduction, and no LDL-C improvement by week 16 represent the cleanest non-responder signal and are candidates for treatment discontinuation or protocol amendment.

Non-Invasive Fibrosis Scores as Early Readouts

FIB-4 and the Enhanced Liver Fibrosis (ELF) score have been explored as surrogate endpoints in resmetirom trials. FIB-4 improvement at 24 weeks correlated modestly with histologic fibrosis improvement at 54 weeks in MAESTRO-NASH exploratory analyses, although the correlation coefficient was not strong enough to replace biopsy [2]. The FDA has not accepted FIB-4 as a standalone surrogate for accelerated approval of liver drugs, as noted in their 2023 draft guidance on non-cirrhotic NASH endpoints [6].

LDL-C as a Pharmacodynamic Marker

Because THR-β agonism upregulates hepatic LDL receptor expression, LDL-C reduction serves as an on-target pharmacodynamic marker [3]. A patient who shows less than 5% LDL-C reduction after 8 weeks of 80 mg resmetirom at confirmed adherence may have subtherapeutic drug exposure (pharmacokinetic interaction, malabsorption, or formulation issue) rather than true non-response. Checking adherence and ruling out an unrecognized CYP2C8 inducer is the first clinical step in this scenario.

Comparing Resmetirom Response Rates With Other MASH Approaches

To contextualize resmetirom's non-responder fraction, comparison with pipeline agents is useful. Lanifibranor (pan-PPAR agonist) showed NASH resolution in 55% of patients at the 1,200 mg dose in the NATIVE trial (N=247), though the patient population differed from MAESTRO-NASH [7]. Semaglutide 2.4 mg showed NASH resolution in 59% of patients with F1-F2 fibrosis in a phase 2 trial (N=320), but did not meet the fibrosis improvement endpoint, limiting its direct comparability [8]. Resmetirom remains the only approved agent, so its non-responder fraction defines the current clinical baseline.

The Endocrine Society's 2023 clinical practice guideline on metabolic liver disease states: "Pharmacologic therapy for MASH should be considered in patients with biopsy-proven F2-F3 fibrosis who have not achieved adequate response to lifestyle intervention, and treatment targets should include both histologic and metabolic endpoints" [9]. That framing reinforces the importance of measuring multiple response dimensions before labeling a patient a non-responder based on a single biomarker.

Practical Monitoring Schedule for Identifying Non-Responders Early

A structured monitoring schedule reduces the time a true non-responder spends on an ineffective and costly therapy (the list price of Rezdiffra is approximately $47,400 per year as of mid-2024).

• Baseline: Liver biopsy or validated non-invasive score, TSH, full lipid panel, HbA1c, LFC by MRI-PDFF if available, comprehensive drug interaction review.
• Week 8: ALT, AST, full lipid panel, TSH. Confirm adherence. If LDL-C has not moved and ALT is unchanged, check for pharmacokinetic interactions.
• Week 12-16: Repeat LFC measurement if available. A relative LFC reduction below 10% is a red-flag threshold.
• Week 24: ALT, AST, lipid panel, HbA1c. Reassess alcohol use. Consider stopping if all biomarkers are unchanged.
• Week 54: Repeat biopsy per MAESTRO-NASH protocol if histologic confirmation of response is required for continued authorization under payer criteria.

The FDA prescribing information for Rezdiffra does not specify a mandatory stopping rule based on biomarker non-response [1], but payer coverage policies increasingly require documented biomarker benefit for continued authorization.